Drugmaker Novo Nordisk has announced that it will significantly reduce insulin prices in the United States beginning next year—a relief for Americans struggling with high prices.
Denmark-based Novo Nordisk will lower U.S. prices of several pre-filled insulin pens and vials by up to 75 percent for people living with Type 1 and Type 2 diabetes, the company said in a press release on Mar. 14. The new prices will come into effect on Jan. 1, 2024. The company’s Novolin and Levemir legacy insulin brands will see a price cut of 65 percent from their current list price. The other two legacy insulin brands, NovoLog and NovoLog Mix 70/30, will see prices reduced by 75 percent.
